We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current IDXG market cap is 2.88M. The company's latest EPS is USD 1.5152 and P/E is 2.59.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 32.89M | 41.65M | 32.06M | 40.21M | 46.93M |
| Operating Income | -26.07M | -14M | -3.62M | 2.8M | 8.11M |
| Net Income | -29.48M | -14.94M | -21.96M | 802k | 6.7M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 45.68M | 38.43M | 15.98M | 13.02M | 14.79M |
| Total Liabilities | 28.23M | 34.31M | 32.52M | 28.16M | 17.01M |
| Total Equity | -29.08M | -42.42M | -63.07M | -61.67M | -2.22M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -13.98M | -8.72M | -7.69M | 3.79M | 4.65M |
| Investing | -1.58M | -315k | 6.21M | -87k | -876k |
| Financing | 16.61M | 8.98M | 3M | -5.03M | -5.81M |
| Market Cap | 2.88M |
| Price to Earnings Ratio | 2.59 |
| Price to Sales Ratio | 0.37 |
| Price to Cash Ratio | 11.87 |
| Price to Book Ratio | -7.82 |
| Dividend Yield | - |
| Shares Outstanding | 4.42M |
| Average Volume (1 week) | 869 |
| Average Volume (1 Month) | 8.06k |
| 52 Week Change | -54.55% |
| 52 Week High | 3.54 |
| 52 Week Low | 0.443325 |
| Spread (Intraday) | 0.2 (25%) |
| Company Name | Interpace Biosciences Inc (QX) |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.interpace.com |
| Industry | business services, nec (7389) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
